Tag Archives: #pharma

FDA’s OPDP Issues Two New Untitled Letters

While enforcement has been at a low ebb for quite some time with FDA’s Office of Prescription Drug Promotion (OPDP), this week took a different turn with the posting of two new untitled letters sent October 31. That brings the … Continue reading

Posted in OPDP, Regulatory Communications | Tagged , , | Comments Off on FDA’s OPDP Issues Two New Untitled Letters

What Happens When You Talk About Adherence in Promotional Communications?

FDA has announced that the Office of Prescription Drug Promotion (OPDP) is planning a study to evaluate the influence that statements made in a promotional communication about patient adherence to a medication may have on the resulting preference for a … Continue reading

Posted in OPDP | Tagged , | Comments Off on What Happens When You Talk About Adherence in Promotional Communications?

Drug Approvals and FDA AdComms in 2023

Having passed the mid-year point, it is always an interesting exercise to take stock of where we stand with respect to the approval of new medicines. Overall, when considering the volume of activity, things would seem to be looking up … Continue reading

Posted in Advisory Committee Prepapartion, FDA Policy | Tagged , , , | Comments Off on Drug Approvals and FDA AdComms in 2023

FDA’s OPDP Issues Third Letter of 2023

For the second time this month and the third time this year, FDA’s OPDP has posted notice that it has taken an enforcement action. Last week, a Warning Letter was posted regarding a sales aid. This week it action came … Continue reading

Posted in FDA Policy, Warning Letters | Tagged , , | Comments Off on FDA’s OPDP Issues Third Letter of 2023

FDA’s OPDP Issues Second Regulatory Action Letter of 2023

In what has been a long period of relative low activity, FDA’s OPDP has taken the opportunity to remind us that low enforcement does not mean no enforcement when it comes to promotional speech by pharmaceutical companies. This past June … Continue reading

Posted in FDA Policy, Warning Letters | Tagged , , | Comments Off on FDA’s OPDP Issues Second Regulatory Action Letter of 2023